WeSearch

STAT+: Novartis doubles down on molecular glue strategy

Meghana Keshavan· ·1 min read · 0 reactions · 0 comments · 2 views
STAT+: Novartis doubles down on molecular glue strategy

Seniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout

Original article
STAT · Meghana Keshavan
Read full at STAT →
Anonymous · no account needed
Share 𝕏 Facebook Reddit LinkedIn Threads WhatsApp Bluesky Mastodon Email

Discussion

0 comments

More from STAT

Opinion: We published in Nature Medicine in 2025 for free. In 2026, it cost us $12,850
STAT·9
Opinion: How long Covid’s scientific stalemate made it politically erasable
STAT·8
STAT+: Scientists see promise in NIH proposal to cap number of grants they receive
STAT·8
STAT+: Private Medicare plans erect barriers to rehab care in pursuit of profit, federal investigators find
STAT·11
STAT+: Pharmalittle: We’re reading about U.S. pressure on European drug prices, longer shortages, and more
STAT·9
Are Republicans turning against medications for treating opioid addiction?
STAT·12